Kintai’s host-targeting niche in Flagship microbiome ecosystem

Flagship’s latest microbiome play Kintai mimics bugs with oral small molecules

Kintai, Flagship’s latest foray into microbiome-based medicines, is taking bugs out of the equation by developing oral small molecules that mimic microbes’ therapeutic effects. Emerging from stealth mode Tuesday and led by Paul-Peter Tak as CEO, the biotech has discovered over 44,000 bacterial genes and hundreds of new metabolites in the gut, and is using that data to develop tissue-targeted therapies.

Kintai Therapeutics Inc. is Flagship Pioneering’s fourth company to

Read the full 705 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE